Eloralintide
Medium EvidenceA selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2.
What It Is
Eloralintide (LY3841136) is a novel, selective amylin receptor agonist developed by Eli Lilly for the treatment of obesity. Unlike GLP-1 receptor agonists, eloralintide works through a distinct amylin-based mechanism — amylin is a peptide hormone co-secreted with insulin that promotes satiety and slows gastric emptying. In a 48-week Phase 2 multicenter, double-blind, randomized, placebo-controlled trial published in The Lancet, all treatment arms met the primary endpoint, demonstrating dose-dependent weight reductions from 9.5% to 20.1% compared to 0.4% with placebo. Notably, eloralintide demonstrated 11.3% additional weight loss when added to tirzepatide therapy, suggesting strong combination potential. The safety profile was favorable, with mild-to-moderate gastrointestinal events and fatigue as the most common adverse effects. Lilly's Phase 3 clinical studies are actively enrolling, and a Phase 2 combination trial with CT-388 is underway. Eloralintide represents a new drug class for obesity — selective amylin agonists — distinct from the GLP-1 and GIP agonists that currently dominate the market, and its combination potential may set a new efficacy ceiling for metabolic therapies.
Regulatory Status
Phase 3 clinical trials enrolling as of late 2025. Not yet approved in any jurisdiction.
Effective: 2025
View FDA SourceWhy Researchers Study It
Eloralintide represents a new class of obesity therapeutics — selective amylin receptor agonists — offering a GLP-1-independent mechanism. Its distinct pathway makes it a prime candidate for combination therapy with GLP-1 agonists, potentially achieving greater weight loss than either mechanism alone. The amylin pathway's role in satiety signaling and gastric emptying is complementary to GLP-1 effects.
Proposed Mechanisms
- Selectively activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus
- Promotes satiety through central appetite suppression via amylin signaling
- Slows gastric emptying to prolong post-meal fullness
- Does not directly engage GLP-1, GIP, or glucagon receptors — independent mechanism of action
- Long-acting design enables once-weekly subcutaneous dosing
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (Phase 2) | Adults with obesity, 48-week, multicenter, double-blind, placebo-controlled (Lancet 2025) | Dose-dependent weight loss: 9.5% to 20.1% vs 0.4% placebo; all arms met primary endpoint | Source |
| Human (Phase 1) | Proof of concept study | Demonstrated target engagement and dose-proportional pharmacokinetics | Source |
Commonly Discussed Benefits
Safety & Cautions
- Phase 3 trials ongoing; not yet FDA-approved
- Higher GI side effects and fatigue reported at higher doses
- Long-term safety and efficacy data from Phase 3 trials not yet available
- Only available through clinical trial enrollment
- Combination therapy data (with CT-388) still pending
Comparisons
See how Eloralintide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
Cagrilintide
High EvidenceA long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.